ESSA Pharma Investor Relations Material
Latest events
AGM 2024
ESSA Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ESSA Pharma Inc
Access all reports
ESSA Pharma Inc. is a clinical-stage pharmaceutical company primarily focused on the development of novel therapies for the treatment of prostate cancer. The company is pioneering the creation of a new class of drugs known as "anitens," which are designed to disrupt the androgen receptor signaling pathway, a key driver in the progression of prostate cancer. ESSA's lead clinical candidate, masofaniten (formerly known as EPI-7386), targets the N-terminal domain of the androgen receptor, aiming to offer a novel approach for patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, especially those who have developed resistance to current anti-androgen therapies. The company is headquartered in Vancouver, Canada, and its shares are listed on the Nasdaq.
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
EPIX
Country
🇺🇸 United States